Chembio Diagnostics Announces Election of Leslie Teso-Lichtman to Its Board of Directors
May 24 2022 - 4:15PM
Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI),
a leading point-of-care diagnostic company focused on
infectious diseases, today announced the election of Leslie
Teso-Lichtman to its Board of Directors at Chembio’s 2022 Annual
Meeting of Stockholders.
“We are excited to have Leslie join the Chembio Board of
Directors,” said Richard Eberly, Chembio’s Chief Executive Officer
and President. “Her significant experience in corporate financial
leadership at global diagnostics companies will be an important
asset as we strive to create value through our Global
Competitiveness program by leveraging Chembio’s broad product
portfolio and operations worldwide.”
Ms. Teso-Lichtman serves as Senior Vice President and Chief
Financial Officer of CereVasc, Inc., where she is responsible for
the accounting, finance, and treasury functions, including
forecasting and capital planning. Previously, Ms. Teso-Lichtman
served as Senior Vice President of Finance and Treasurer for Roche
Diagnostics Hematology from 2011 to 2014, following Roche’s
acquisition of her former employer Constitutional Medical
Investors, Inc. Ms. Teso-Lichtman worked on the integration plan
for the new company and to achieve milestones in connection with
the acquisition. Prior to her time at Constitutional Medical, Ms.
Teso-Lichtman held the role of Vice President and Controller at
Cytyc Corporation, which was acquired by Hologic, Inc. in 2007,
where she was responsible for all finance and accounting
activities, including completing three acquisitions.
“I am thrilled to join the Chembio Board of Directors as the
true value of point-of-care diagnostics has been realized and
elevated in the global healthcare system,” said Ms. Teso-Lichtman.
“Chembio has multiple differentiated platforms that benefit patient
needs globally. I look forward to contributing as the company
embarks on its next phase of growth.”
About Chembio DiagnosticsChembio is a leading
diagnostics company focused on developing and commercializing
point-of-care tests used to detect and diagnose infectious
diseases, including sexually transmitted disease, insect vector and
tropical disease, COVID-19 and other viral and bacterial
infections, enabling expedited treatment. Coupled with Chembio’s
extensive scientific expertise, its novel DPP technology offers
broad market applications beyond infectious disease. Chembio’s
products are sold globally, directly and through distributors, to
hospitals and clinics, physician offices, clinical laboratories,
public health organizations, government agencies, and consumers.
Learn more at www.chembio.com.
DPP is Chembio’s registered trademark, and the Chembio logo is
Chembio’s trademark. For convenience, these trademarks appear in
this release without ® or ™ symbols, but that practice does not
mean that Chembio will not assert, to the fullest extent under
applicable law, its rights to the trademarks.
Contact:Philip TaylorGilmartin Group(415)
937-5406investor@chembio.com
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Chembio Diagnostics (NASDAQ:CEMI)
Historical Stock Chart
From Sep 2023 to Sep 2024